NCT02959983已完成4 期
A Phase 4 Multicenter, Multinational, Prospective, Randomized, Placebo-Controlled, Double-Blinded Parallel Group Study to Assess Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) in Patients Who Report Inadequate Control of IBS-D Symptoms With Prior Loperamide Use (RELIEF)
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 346
- 试验地点
- 79
- 主要终点
- Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain And Daily Stool Consistency Scores
研究概览
简要总结
This study will evaluate the efficacy and safety of eluxadoline 100 milligrams (mg) twice a day (BID) versus placebo for the treatment of patients with Irritable Bowel Syndrome with Diarrhea (IBS-D) who report that the use of loperamide in the prior 12 months failed to provide control of their IBS-D symptoms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has a diagnosis of IBS-D, defined by the Rome III criteria as loose (mushy) or watery stools ≥25% and hard or lumpy stools ≤25% of bowel movements.
- •Has had a colonoscopy performed within 5 years prior to Screening if they are at least 50 years of age, OR if they meet any of the following alarm features:
- •Has documented weight loss within the past 6 months; or
- •Has nocturnal symptoms; or
- •Has a familial history of colon cancer; or
- •Has blood mixed with their stool (excluding any blood from hemorrhoids)
- •Patient reports use of loperamide in the 12 months prior to Screening for IBS-D symptoms and that loperamide did not provide adequate control of IBS-D symptoms.
- •Has not used any loperamide rescue medication within 14 days prior to randomization.
排除标准
- •Has a diagnosis of Irritable Bowel Syndrome (IBS) with a subtype of constipation IBS, mixed IBS, or unsubtyped IBS.
- •Has a history of inflammatory or immune-mediated gastrointestinal (GI) disorders including inflammatory bowel disease (i.e., Crohn's disease, ulcerative colitis), microscopic colitis, or celiac disease.
- •Has a history of diverticulitis within 3 months prior to screening.
- •Has a documented history of lactose intolerance.
- •Has a documented history of bile-acid malabsorption.
- •Has a history of chronic or severe constipation or intestinal obstruction, stricture, toxic megacolon, GI perforation, fecal impaction, gastric banding, bariatric surgery, adhesions.
- •Has any of the following surgical history:
- •Cholecystectomy or previously documented agenesis of gallbladder; or
- •Any abdominal surgery within the 3 months prior to screening; or
- •Major gastric, hepatic, pancreatic, or intestinal surgery (appendectomy, hemorrhoidectomy, or polypectomy greater than 3 months post-surgery are allowed).
- •Has a history of cholecystitis within 6 months before screening.
- •Has a history of pancreatitis or structural diseases of the pancreas, including known or suspected pancreatic duct obstruction.
- •Has a history of known or suspected biliary duct obstruction or sphincter of Oddi disease or dysfunction, excluding a history of gallstones.
- •Has a history or current evidence of laxative abuse within 5 years prior to screening.
- •Has documented evidence of cirrhosis.
- •Has a history of cardiovascular events, including stroke, myocardial infarction, congestive heart failure, or transient ischemic attack within 6 months prior to screening.
- •Has an unstable renal, hepatic, metabolic, or hematologic condition.
- •Has a history of malignancy within 5 years before screening (except squamous and basal cell carcinomas and cervical carcinoma in situ).
- •Has a history of human immunodeficiency virus infection.
- •Has a history of Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision-defined substance dependency, excluding nicotine and caffeine, within 2 years prior to screening.
- •Has a history of alcohol abuse, alcohol addiction, and alcoholism or drinks more than 3 alcoholic beverages per day.
- •Has used aspirin or aspirin-containing medications (>325 mg of aspirin per day) or nonsteroidal anti-inflammatory drugs, when taken specifically for the symptoms of IBS, within 14 days of randomization.
- •Has current (within 14 days of randomization) or expected use of any narcotic or opioid-containing agents, tramadol, docusate, enemas, GI preparations (including antacids containing aluminum or magnesium, antidiarrheal agents [except loperamide rescue medication after randomization]), antinausea agents, antispasmodic agents, bismuth, or prokinetic agents.
- •Has current (within 28 days of randomization) use of rifaximin or other antibiotics (with the exception of topical antibiotics or a 1-day course with an antibiotic). Expected use of rifaximin or other antibiotics during the course of the study that is known at the time of randomization.
- •Has an elective surgery planned or expects to need elective surgery at any time during the study.
研究组 & 干预措施
Eluxadoline
Active Comparator
Eluxadoline 100 mg oral tablets twice daily (BID) with food for 12 weeks.
干预措施: Eluxadoline (Drug)
Placebo
Placebo Comparator
Placebo matching eluxadoline oral tablets BID with food for 12 weeks.
干预措施: Placebo (Drug)
结局指标
主要结局
Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain And Daily Stool Consistency Scores
时间窗: Baseline, Weeks 1 to 12
Percentage of primary composite responders is defined as the percentage of participants who meet both of the following daily composite criteria for at least 50% of the days with diary entry: 1)Worst Abdominal Pain (WAP) score improved by ≥40% compared to Baseline. The participant records their WAP score in the past 24 hours each day in a daily patient diary where: 0=no pain to 10=worst imaginable pain. 2) Bristol Stool Score (BSS) \<5; or the absence of a bowel movement if accompanied by ≥40% improvement in WAP compared to Baseline. The participant records their stool consistency each day in a daily patient diary using the BSS on a scale from 1 (hard stool) to 7 (watery stool).
次要结局
- Percentage of Pain Responders(Baseline, Weeks 1 to 12 and 4-week intervals (Weeks 1 to 4, Weeks 5 to 8 and Weeks 9 to 12))
- Percentage of Monthly Composite Responders(Weeks 1 to 4, 5 to 8, and 9 to 12)
- Percentage of Stool Consistency Responders(Weeks 1 to 12 and 4-week intervals (Weeks 1 to 4, Weeks 5 to 8 and Weeks 9 to 12))
研究者
研究点 (79)
Loading locations...
相似试验
已完成
4 期
A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)Uncontrolled GoutChronic GoutNCT04762498Amgen54
已完成
3 期
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial SpondyloarthritisAxial SpondyloarthritisNCT02757352Eli Lilly and Company303
已完成
2 期
A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung CancerNon-small Cell Lung Cancer (NSCLC)NCT03693300AstraZeneca117
已完成
3 期
A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial SpondyloarthritisSpondyloarthritisNCT02696785Eli Lilly and Company341
已完成
2 期
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)Relapsed/Refractory RhabdomyosarcomaNon-rhabdomyosarcoma Soft Tissue SarcomaEwing SarcomaNCT03441360Eisai Inc.23